Javan-Noughabi J, et al. - A cost-effectiveness analysis was performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran to evaluate the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer. Researchers divided patients into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. They reported that AC was a simple dominate strategy. It was observed that AC was estimated to have a lower cost and greater effectiveness than PG.